Nouscom

Nouscom is a cancer vaccine company whose lead product, Nous209, is an off-the-shelf vaccine in clinical trials for the treatment of patients who carry mutations in certain DNA repair mechanisms (Lynch syndrome). The company is also developing personalized vaccines formulated to address the specific mutation profiles of individual patients’ tumors.